Profile data is unavailable for this security.
About the company
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to overseas markets.
- Revenue in CNY (TTM)25.25bn
- Net income in CNY5.43bn
- Incorporated1997
- Employees19.61k
- LocationJiangsu Hengrui Pharmaceuticals Co LtdNo.7 Kunlunshan RoadLianyungang Eco & Tech Development ZoneLIANYUNGANG 222000ChinaCHN
- Phone+86 51 881220983
- Fax+86 51 885453845
- Websitehttps://www.hengrui.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biogen Inc | 67.88bn | 8.13bn | 195.06bn | 7.57k | 24.04 | 1.75 | 16.07 | 2.87 | 7.94 | 7.94 | 66.42 | 109.05 | 0.3723 | 1.23 | 4.60 | 1,277,675.00 | 4.46 | 12.53 | 5.07 | 14.83 | 75.54 | 83.04 | 11.97 | 26.93 | 1.48 | 2.87 | 0.2837 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
Otsuka Holdings Co Ltd | 106.57bn | 6.20bn | 225.14bn | 34.39k | 35.33 | 1.71 | 19.50 | 2.11 | 233.68 | 233.68 | 4,016.84 | 4,829.27 | 0.6256 | 2.34 | 4.50 | 63,393,040.00 | 3.76 | 4.80 | 4.70 | 5.88 | 70.66 | 68.21 | 6.01 | 8.36 | 1.66 | -- | 0.0851 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
Bayer AG | 365.96bn | -9.83bn | 232.33bn | 96.57k | -- | 0.8381 | 4.25 | 0.6349 | -1.29 | -1.29 | 47.96 | 36.33 | 0.3901 | 1.47 | 3.47 | 472,438.70 | -1.04 | -1.79 | -1.42 | -2.38 | 58.07 | 59.02 | -2.67 | -4.80 | 0.8573 | 2.94 | 0.5651 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
UCB SA | 42.37bn | 1.86bn | 250.43bn | 9.08k | 134.73 | 3.51 | 34.52 | 5.91 | 1.23 | 1.23 | 27.92 | 47.19 | 0.3518 | 1.71 | 4.26 | 600,462.40 | 1.55 | 5.03 | 1.88 | 6.28 | 67.80 | 72.21 | 4.40 | 12.66 | 0.7806 | 3.15 | 0.2534 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
Takeda Pharmaceutical Co Ltd | 215.74bn | 7.33bn | 322.61bn | 49.28k | 44.12 | 0.8346 | 7.34 | 1.50 | 94.03 | 94.03 | 2,798.45 | 4,970.05 | 0.2845 | 1.26 | 5.70 | 89,550,420.00 | 0.9677 | 1.65 | 1.15 | 1.97 | 66.18 | 68.05 | 3.40 | 6.06 | 0.7427 | 2.63 | 0.4127 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
Jiangsu Hengrui Pharmaceuticals Co Ltd | 25.25bn | 5.43bn | 333.62bn | 19.61k | 61.24 | 7.83 | -- | 13.21 | 0.854 | 0.854 | 3.98 | 6.68 | 0.5603 | 1.65 | 4.16 | 1,287,652.00 | 12.02 | 13.68 | 13.22 | 15.20 | 84.74 | 85.87 | 21.45 | 20.01 | 6.76 | -- | 0.0079 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
Haleon PLC | 104.97bn | 10.14bn | 337.83bn | 24.00k | 33.60 | 2.17 | 192.71 | 3.22 | 0.1176 | 0.1176 | 1.22 | 1.82 | 0.3333 | 2.92 | 5.10 | 469,083.30 | 3.36 | -- | 4.00 | -- | 61.56 | -- | 10.08 | -- | 0.5775 | 7.53 | 0.3465 | -- | 4.09 | -- | -1.04 | -- | -- | -- |
Sun Pharmaceutical Industries Ltd | 41.16bn | 8.69bn | 385.31bn | 43.00k | 44.32 | -- | 35.25 | 9.36 | 43.32 | 43.32 | 205.18 | -- | -- | -- | -- | 11,443,900.00 | -- | 7.77 | -- | 10.85 | 78.50 | 71.59 | 21.35 | 14.23 | -- | 81.23 | -- | 38.64 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
Daiichi Sankyo Co Ltd | 82.47bn | 11.20bn | 448.78bn | 18.73k | 39.45 | 5.23 | 31.50 | 5.44 | 119.51 | 119.51 | 879.76 | 901.38 | 0.5574 | 1.06 | 3.61 | 90,090,090.00 | 7.58 | 4.99 | 9.48 | 6.14 | 75.30 | 69.10 | 13.60 | 9.94 | 2.44 | -- | 0.0558 | 51.87 | 25.28 | 11.49 | 85.90 | 16.67 | 13.01 | 16.47 |
Data as of Sep 30 2024. Currency figures normalised to Jiangsu Hengrui Pharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
E Fund Management Co., Ltd.as of 30 Jun 2024 | 215.72m | 3.39% |
China Asset Management Co., Ltd.as of 31 Mar 2024 | 92.08m | 1.45% |
China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 88.36m | 1.39% |
Zhong Ou Asset Management Co., Ltdas of 30 Sep 2023 | 79.46m | 1.25% |
ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 59.48m | 0.93% |
China Investment Corp. (Investment Management)as of 30 Sep 2023 | 58.11m | 0.91% |
HuaAn Fund Management Co., Ltd.as of 31 Dec 2023 | 43.40m | 0.68% |
Huatai-PineBridge Fund Management Co., Ltd.as of 31 Dec 2023 | 36.82m | 0.58% |
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 35.17m | 0.55% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 31.69m | 0.50% |
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.